Fabio Frigerio

Title: **Fabio Frigerio: Innovator in Neurological Treatments**

Introduction

Fabio Frigerio, based in Milan, Italy, is a prominent inventor known for his groundbreaking work in pharmaceuticals. With a keen focus on neurological and psychiatric disorders, Frigerio has made significant strides in the field of medicinal chemistry.

Latest Patents

Frigerio holds a patent related to "Heterocyclylmethylidene derivatives and their use as modulators of mGluR5 receptors." This innovative invention relates to compounds that act as allosteric modulators of mGluR5 receptor activity. The patent showcases pharmaceutical compositions that can be used to treat or prevent neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia, cognitive decline, and dementia.

Career Highlights

Currently, Frigerio is associated with Recordati Industria Chimica e Farmaceutica S.p.A., a company recognized for its commitment to developing advanced pharmaceuticals. Frigerio's expertise in chemistry and pharmacology has propelled his career into notable heights, leading to valuable contributions in drug development.

Collaborations

Throughout his career, Frigerio has worked alongside talented colleagues, including Carlo Riva and Davide Graziani. These collaborations have fostered an environment of innovation, enhancing the potential for groundbreaking discoveries in the pharmaceutical industry.

Conclusion

Fabio Frigerio's dedication to inventing solutions for complex neurological issues highlights his role as a key figure in modern medicine. His patent for Heterocyclylmethylidene derivatives signifies an important advancement that may pave the way for new treatments aimed at alleviating the impact of glutamate dysfunction in various psychiatric conditions.